Cargando…

Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment

Several molecular-targeted agents have been tested as first- or second-line therapies for hepatocellular carcinoma (HCC) but failed to improve clinical outcomes; sorafenib has been the only approved systemic agent for treating HCC for almost 10 years. Regorafenib resulted in a significant improvemen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Bo Hyun, Park, Joong-Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Liver Cancer Association 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035683/ https://www.ncbi.nlm.nih.gov/pubmed/37383078 http://dx.doi.org/10.17998/jlc.2021.09.23

Ejemplares similares

Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations
por: Storandt, Michael H, et al.
Publicado: (2022)

Targeted agents for second-line treatment of advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2019)

Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma
por: Rimassa, Lorenza, et al.
Publicado: (2020)

Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
por: Trojan, Jörg, et al.
Publicado: (2016)

Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors
por: Piñero, Federico, et al.
Publicado: (2020)

First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma—An Update on Patient Selection and Response Evaluation
por: von Felden, Johann, et al.
Publicado: (2016)

Second-line treatment options in hepatocellular carcinoma
por: Marino, Donatella, et al.
Publicado: (2019)

Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?
por: Rajappa, Senthil, et al.
Publicado: (2022)

Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma
por: Sugimoto, Rie, et al.
Publicado: (2022)

Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
por: Kelley, Robin Kate, et al.
Publicado: (2020)

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
por: Kaseb, Ahmed O, et al.
Publicado: (2016)

Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice
por: Jain, Ankit, et al.
Publicado: (2021)

First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review
por: Zhang, Lan, et al.
Publicado: (2022)

Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials
por: Han, Yue, et al.
Publicado: (2021)

Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
por: Chiang, Chi-leung, et al.
Publicado: (2021)

Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis
por: Park, Joon Oh, et al.
Publicado: (2016)

Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis
por: Solimando, Antonio Giovanni, et al.
Publicado: (2021)

Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation
por: Kim, Bo Hyun, et al.
Publicado: (2018)

Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States
por: Sieg, Maximilian, et al.
Publicado: (2020)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Kim, Tae Hyun, et al.
Publicado: (2023)

Noninvasive imaging-based machine learning algorithm to identify progressive disease in advanced hepatocellular carcinoma receiving second-line systemic therapy
por: Dong, Wei, et al.
Publicado: (2023)

Surveillance for hepatocellular carcinoma: It is time to move forward
por: Kim, Bo Hyun, et al.
Publicado: (2022)

Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations
por: Debaillon Vesque, Audrey, et al.
Publicado: (2020)

Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study
por: Saeed, Anwaar, et al.
Publicado: (2020)

Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction
por: Pathak, Surabhi, et al.
Publicado: (2021)

Systemic therapy in advanced hepatocellular carcinoma
por: Ahn, Joseph C., et al.
Publicado: (2023)

Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy
por: Bonafede, Machaon M., et al.
Publicado: (2019)

The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea
por: Cho, Yuri, et al.
Publicado: (2023)

Efficacy and Safety of Second-line Treatments in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: A Meta-analysis
por: An, Limin, et al.
Publicado: (2021)

Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma
por: Tazi, El Mehdi, et al.
Publicado: (2011)

Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials
por: Wang, Dongxu, et al.
Publicado: (2020)

Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching
por: Adhoute, Xavier, et al.
Publicado: (2022)

Sorafenib combined with radiation therapy for advanced hepatocellular carcinoma with portal and hepatic vein invasion extending to the inferior vena cava: a complete response case according to modified RECIST criteria
por: Cho, Yuri, et al.
Publicado: (2022)

Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma
por: Cho, Yuri, et al.
Publicado: (2023)

Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma
por: Aitcheson, Gabriella, et al.
Publicado: (2021)

Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis
por: Qin, He-nan, et al.
Publicado: (2022)

Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond
por: Feng, Maple Ye, et al.
Publicado: (2022)

Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
por: Kudo, Masatoshi
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a6g4rlnpqgip60qmrivodl733f